The first-line treatment of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS syndrome) induces a response and survival rate of approximately 85%, even if a considerable number of patients relapse; nevertheless, a number of these patients are resistant to conventional management. Immunoablation followed by stem cell transplantation has been shown to be capable of inducing remissions in a large spectrum of experimental autoimmune disorders. We report here the case of a 20-year-old male patient with the TTP-HUS syndrome who was resistant to conventional treatment and was transplanted with autologous immunoselected CD34 + PBPC after conditioning with cyclosphosphamide, anti-T lymphocyte globulin and prednisone. Seven months after transplant the patient is alive and well, without any further treatment being given.
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is recognized as being part of a clinical spectrum consisting of thrombocytopenia and hemolysis with ischemic manifestations in various organs affected by the microvascular occlusions originally described by Moschcowitz. 1 The observation of macrophage/lymphocyte activation in the TTP-HUS syndrome suggests the possibility that immunological events may be involved in this disorder. In addition, increased plasma levels of interleukin (IL)-1, IL-6, soluble IL-2 receptor and TNF and autoantibodies against antiphospholipid and glycoprotein (GP) IV (CD36) have been reported. 2 The first-line treatment of the TTP-HUS syndrome is based on plasma-exchange, which induces a response and survival rate of approximately 85%, and in addition glucocorticoids, immunoadsorption, vincristine and intravenous immunoglobulin (IVIG). 3 However, a Immunoablation followed by allogeneic stem cell (SC) transplantation has been shown to be capable of inducing favorable results in a large spectrum of experimental autoimmune disorders, hereditary and/or induced. Similar results, albeit with some exceptions, have been obtained in human patients affected by coincidental autoimmune and blood diseases. However, autologous SC are being increasingly utilized worldwide in the treatment of severe autoimmune disease (SAD), [6] [7] [8] [9] because of the significantly lower transplant-related mortality (TRM). We report here a case of a young man affected by TTP-HUS syndrome resistant to conventional therapy successfully treated with CD34 + autologous peripheral blood precursor and stem cell transplantation (PBPC).
Case report
A 20-year-old man was hospitalized because of confusion, limb paraesthesia, anemia (Hb: 7.7 g/dl), thrombocytopenia (platelets: 21 × 10 9 /l), impaired renal function (creatinine 0.156 g/l) and high LDH and bilirubin levels (1068 U/l and 0.2 g/l). A diagnosis of TTP-HUS syndrome was made, other underlying autoimmune and immunodeficiency syndromes inducing a secondary TTP being excluded (antinuclear (ANA), antiDNA (ADNA) tests and HIV serostatus were negative). The patient was treated with plasmaexchange (28 procedures) and prednisone (2 mg/kg) daily and successively with weekly pulses of vincristine (1 mg i.v. for 3 weeks) and intravenous immunoglobulin 400 mg/kg/day for 5 days (IVIG).
As there was no response an autologous SC transplantation procedure, after approval of the local ethical committee, was proposed and formally accepted by the patient and his family. Peripheral blood progenitor cells (PBPC) were mobilized with cyclophosphamide (Cy) 4 g/m 2 plus G-CSF 300 g/day. After this procedure a decrease in LDH levels was registered (LDH: 380 U/l), with concomitant normaliz- 9 /l was achieved on day +6; platelet count never fell below 50 × 10 9 /l. No parenteral administration of antibiotics was necessary. There were no transfusion requirements and the patient was discharged 10 days after PBPC reinfusion. Seven months after the transplant the patient is well and in a normal hematological state without any further treatment being given. Figure 1 summarizes the follow-up with reference to the relevant hematological parameters.
Discussion
Thanks to the progress of treatment during the past decade in patients diagnosed with TTP-HUS syndrome the response rate has increased from 5% to more than 90%, with a concomitant decrease of mortality rate from 95% to less than 20%. However, a 68% rate of relapse after initial remission has been reported, mostly in the first 2 months.
In this case no response was noted after standard treatment, suggesting an aggressive immunosuppression such as autologous PBPC transplant. We were encouraged to do this because of the good tolerance reported up to now in the literature and by the excellent results in SAD patients who received this type of treatment in our Institution. This is the first case of refractory TTP-HUS syndrome treated successfully with autologous SC transplantation in the literature.
The immunosuppressive effect would seem to be the main mechanism of autologous SC transplantation. In addition, the high dose of Cy used as mobilization regimen by itself most probably strengthens the subsequent immunosuppression due to conditioning regimen. This impression is supported by the immune recovery pattern, which shows a reduction of the CD4 + cells and of the CD45RA + /CD45RO + ratio. 10 However, the real impact of autologous transplants on TTP-HUS syndrome depends on further clinical experience, and will need to be carefully compared with other, better known treatments.
